Cervical cancer screening study using light detection
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new light-based device to screen for cervical cancer. It may help find cancer earlier in people with certain HPV types or abnormal Pap tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a cervix that is not deformed.
- You have had a positive test for HPV type 16 or 18, or another high-risk HPV type, along with an abnormal Pap test (ASC-US or worse).
- You agree to take part in the study and have given your informed consent.
- You have never had cervical cancer or any other cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new light-based device to screen for cervical cancer. It is for people who already have abnormal screening results (like high-risk HPV and an abnormal Pap test).
This trial tests a light-based treatment (photodynamic therapy) for high-grade or persistent low-grade abnormal cells in the cervix or vagina. It aims to destroy these cells without surgery, which may be an option for patients who want to avoid more invasive procedures.
This study is testing a new, non-invasive way to screen for cervical cancer. It uses a photoelectric device and an epigenetic test done on a sample from your cervix. The goal is to find early signs of cancer more accurately than current methods.
This study tests a special light-based treatment (called HAL-PDT) for early cervical changes (CIN2) that were found on a recent biopsy. The goal is to see if this treatment can safely remove these changes and prevent them from becoming cancer.
This study tests a new technology to help find cervical cancer earlier by focusing on people who already had an abnormal screening result. It may help improve how abnormal tests are checked and diagnosed.
This trial tests a light-activated drug (ALA-PDT) to treat low-grade cervical changes caused by HPV 16 or 18. It may help clear the virus and prevent progression to more serious disease.
Hear when a new Uterine Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.